Devising a patent strategy to protect the IP of biologics in light of ambiguities, loopholes and pitfalls in the regulatory scheme

Author： Hsing Benjamin C   Palla Sapna W  

Publisher： Future Science

ISSN： 2046-8954

Source： Pharmaceutical Patent Analyst, Vol.2, Iss.2, 2013-03, pp. : 153-155

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Biologics Safety Preclinical, Clinical and Regulatory

By Hennig Renald  

Expert Opinion on Drug Safety, Vol. 2, Iss. 6, 2003-11 ,pp. : 609-611

Informa Healthcare

Access to resources Recommend Favorite

Regulatory Review of Abbreviated Biologics Regulations in ICH Countries

By  

Applied Clinical Research, Clinical Trials and Regulatory Affairs, Vol. 1, Iss. 3, 2014-01 ,pp. : 169-175

Bentham Science Publishers

Access to resources Recommend Favorite

Simple Strategy to Protect Lactase Activity in Solid Formulation

By  

Current Drug Delivery, Vol. 15, Iss. 2, 2018-02 ,pp. : 215-218

Bentham Science Publishers

Access to resources Recommend Favorite

A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?

By Kontoghiorghes George J  

Expert Opinion on Drug Safety, Vol. 12, Iss. 5, 2013-09 ,pp. : 605-609

Informa Healthcare

Access to resources Recommend Favorite

Comment on: A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?

By Riva Alessandro  

Expert Opinion on Drug Safety, Vol. 12, Iss. 5, 2013-09 ,pp. : 793-795

Informa Healthcare

Access to resources Recommend Favorite